|
|
|
|
|
|
Delve into the latest advancements and applications driving the evolution of AAV-based treatments, showcasing how innovative research paves the way for transformative medical breakthroughs.
|
|
|
|
|
Accurately measuring viral titer is a key metric throughout gene therapy development, whether you are in the early stage, scaling production, or running assays for quality control release. Learn how droplet digital PCR (ddPCR) technology offers the accuracy to quantify AAV viral titers to support many aspects of AAV-based gene therapy development.
|
|
|
|
|
Understanding the consistency of your AAV gene therapy iterations is essential for making developmental strides. Explore various approaches to addressing AAV vector challenges, navigating the process of viral characterization, and learning how to overcome developmental hurdles in AAV-based gene therapy.
|
|
|
|
|
Regulatory agencies recommend a diverse set of accurate, precise, and specific assays, including at least one bioassay. Read about the current state of the industry, challenges associated with potency assays, and measuring product potency throughout the manufacturing process.
|
|
|
|
|
While characterization and analytical assays are critical to AAV lot release, method development and process optimization are essential to obtain crucial yield and purity. Explore how novel resin chemistries achieve high recovery yields and excellent impurity clearance in an AAV purification workflow.
|
|
|
|
|
For vector-based therapeutics, testing for replication-competent viruses ensures safe treatment, but current strategies lengthen lot release times. Droplet digital PCR (ddPCR) offers an attractive orthogonal method with high sensitivity and fast turnaround time, accelerating the development of a new wave of gene therapies.
|
|
|
|
|
|
|
|
|
|
|
